FRNM FRNM
Company Profile ↓Company Overview
FRNM (FRNM) is a publicly traded company listed on with a market capitalization of $1.16B. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Generates a return on equity of 17.4%, reflecting efficient use of shareholder capital.
Revenue has grown at a 955.1% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $30.41M (+955.1% YoY); net profit $-219.34M.
- Trailing 12 Months Year-on-year growth — revenue +955.1%.
- 5-Year Trend Long-term compounding — revenue CAGR 955.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 955.14% |
| 1 Year: | 955.14% |
Stock Price Performance
| 1 Year: | +3.22% |
| 6 Months: | -22.07% |
| 3 Months: | -3.02% |
| 1 Month: | -5.13% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)46.31 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 955.1% over 5 years.
CONS
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Revenue | 2.88M | 30.41M |
| Cost of Revenue | 2.56M | 1.94M |
| Gross Profit | 318.00K | 28.46M |
| Operating Expenses | 292.29M | 251.93M |
| Operating Income | -291.97M | -223.47M |
| EBITDA | -258.55M | -192.17M |
| Interest Expense | 0 | 2.82M |
| Pretax Income | -274.42M | -219.34M |
| Tax Provision | - | - |
| Net Income | -274.42M | -219.34M |
| Diluted EPS | -2.65 | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Total Assets | 551.92M | 507.05M |
| Current Assets | 252.60M | 226.49M |
| Cash & Equivalents | 67.05M | 78.56M |
| Inventory | - | - |
| Receivables | 1.66M | 1.31M |
| Total Liabilities | 1.61B | 1.77B |
| Current Liabilities | 41.88M | 40.53M |
| Long Term Debt | - | 102.50M |
| Total Debt | 206.52M | 311.62M |
| Total Equity | -1.06B | -1.26B |
| Shares Outstanding | 106.10M | 106.10M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Operating Cash Flow | -196.37M | -110.67M |
| Investing Cash Flow | -52.81M | 21.38M |
| Financing Cash Flow | 263.99M | 100.76M |
| Capital Expenditure | -60.41M | -21.05M |
| Free Cash Flow | -256.78M | -131.72M |
| Net Change in Cash | 14.81M | 11.47M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Gross Margin % | 11.0% | 93.6% |
| Operating Margin % | -10,130.9% | -734.9% |
| Net Margin % | -9,521.9% | -721.3% |
| ROE % | 26.0% | 17.4% |
| ROCE % | -57.2% | -47.9% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for FRNM
Guardant Health, Thursday's Stock Of The Day, Spikes After Hiking 2026 Outlook
Guardant Health is Thursday's IBD Stock Of The Day in a thriving market for colon cancer screening tests. On Friday, Guardant Health stock surged after the company raised full-year outlook after a Q2 revenue beat late Thursday. Several an…
FDA Approves Freenome’s SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.
Freenome is a biotech company focused on developing blood tests to detect cancer early and make screening accessible for everyone. – Approval expands colorectal cancer screening options for the up to 60 million Americans who are overdue for…
FRNM — Frequently Asked Questions
What is the current share price of FRNM?
As of 2026-08-05 17:25 PDT, FRNM trades at $10.91 on NASDAQ/NYSE. Its 52-week range is $9.99 to $14.20.
What is the market capitalisation of FRNM?
FRNM has a market capitalisation of $1.16B on NASDAQ/NYSE.
What is the P/E ratio of FRNM?
FRNM trades at a trailing price-to-earnings (P/E) ratio of -4.12. Its price-to-book (P/B) ratio is -0.92.
What is the return on equity (ROE) of FRNM?
FRNM has a return on equity (ROE) of 17.36%. Its return on capital employed (ROCE) is -47.90%.
Is FRNM a good stock to buy?
This page provides a data-driven analysis of FRNM, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.